Hepatitis C is a liver infection caused by the hepatitis C virus. Hepatitis C can range from a mild illness lasting a few weeks to a serious, lifelong illness. Hepatitis C is often described as “acute,” meaning a new infection or “chronic,” meaning lifelong infection. The virus is most commonly spread through sharing needles syringes, or other equipment used to inject drugs; accidental needle-sticks in healthcare settings; and being born to a mother who is already infected. VA research into hepatitis C addresses prevention, treatment, and managing quality of life.
Search results were generated based on the search term "Hepatitis C". Results are updated weekly, as new data are available.
VIEW: Citations | Publication Briefs | Studies | HSR&D Briefs, Reports, Newsletters | Topic Spotlight | Cyberseminars | Videos | Podcasts | Other Resources
(5 of more than 380 HEPATITIS C focused publications)
- Chen Q, Ayer T, Bethea E, Kanwal F, Wang X, Roberts M, Zhuo Y, Fagiuoli S, Petersen J, Chhatwal J. Changes in hepatitis C burden and treatment trends in Europe during the era of direct-acting antivirals: a modelling study. BMJ open. 2019 Jun 11; 9(6):e026726.
- Chhatwal J, Chen Q, Bethea ED, Hur C, Spaulding AC, Kanwal F. The impact of direct-acting anti-virals on the hepatitis C care cascade: identifying progress and gaps towards hepatitis C elimination in the United States. Alimentary pharmacology & therapeutics. 2019 Jul 1; 50(1):66-74.
- Chhatwal J, Chen Q, Wang X, Ayer T, Zhuo Y, Janjua NZ, Kanwal F. Assessment of the Feasibility and Cost of Hepatitis C Elimination in Pakistan. JAMA Network Open. 2019 May 3; 2(5):e193613.
- Zou WY, Choi K, Kramer JR, Yu X, Cao Y, El-Serag HB, Kanwal F. Risk of Hepatocellular Cancer Recurrence in Hepatitis C Virus+ Patients Treated with Direct-Acting Antiviral Agents. Digestive diseases and sciences. 2019 Apr 30.
- Voils CI, King HA, Thorpe CT, Blalock DV, Kronish IM, Reeve BB, Boatright C, Gellad ZF. Content Validity and Reliability of a Self-Report Measure of Medication Nonadherence in Hepatitis C Treatment. Digestive diseases and sciences. 2019 Apr 29.
» View more Citations
(5 of more than 17 HEPATITIS C focused publication briefs)
- VA Successfully Implements Interferon-free Treatment for Hepatitis C Virus in Previously Undertreated Patient Populations
This study examined the adoption of interferon-free treatment for hepatitis C virus (HCV) in VA to learn who received this therapy and whether the limitations of interferon-containing treatments have been overcome, including low rates of use among VA healthcare users who are African American or Hispanic, and among those with HCV-HIV co-infection. Findings showed that with the advent of interferon-...
Date: March 7, 2018
- HCV-Related Complications Increasing among Women Veterans
This study examined gender-related differences in the incidence and prevalence of cirrhosis, decompensated cirrhosis, and hepatocellular cancer (HCC) between 2000 and 2013. Findings showed that the incidence and prevalence of hepatitis C virus (HCV) complications was higher in men than in women. However, the rate of increase in the incidence rates of cirrhosis and decompensated cirrhosis among HCV...
Date: November 1, 2017
- Direct-Acting Antiviral Agents Reduce Risk of Hepatocellular Cancer among Veterans with Hepatitis C
This study examined the risk of hepatocellular cancer (HCC) following sustained virological response (SVR) among 22,500 Veterans with hepatitis C virus (HCV) who received directing-acting antivirals (DAA) treatment at any of 129 VA hospitals between January and December 2015. Findings showed that in Veterans treated with DAAs, SVR was associated with a 76% reduction in the risk of developing hepat...
Date: October 1, 2017
- VA Hepatitis C Care and Experiences with the Choice Program
This study examined perspectives and experiences with the VA Choice Program among Veterans with HCV and their providers at three VAMCs in the New England region. Findings showed that the Choice Program has the potential to increase Veterans’ access to hepatitis C virus (HCV) treatment, but Veterans and VA providers described substantial problems in the initial years of the program. Four main theme...
Date: March 3, 2017
- Engagement in Hepatitis C Virus Care among Homeless and non-Homeless VA Patients
This study sought to describe engagement in hepatitis C virus (HCV) care among homeless and non-homeless Veterans in the new era of HCV treatment, which includes direct-acting agents (DAAs) with shorter treatment durations, fewer side effects, and higher sustained virologic response (SVR) rates than the older treatment regimens. Findings showed that VA providers do a better job of testing for and ...
Date: March 1, 2017
» View more Publication Briefs
( 5 of more than 27 HEPATITIS C focused projects
|| Advanced Prediction Models to Optimize Treatment and Access for Veterans with Hepatitis C
|| Quality of Care for Hepatitis C in Veterans Who Are Homeless
|| Care for Women Veterans with Hepatitis C Virus Infection
|| Web-based Intervention to Reduce Alcohol Use in Veterans with Hepatitis C
|| Cost-effective Uses of New Hepatitis C Treatments and their VA Budgetary Impact
» View more Studies
There are currently no spotlight features on this topic.
The most recent "Hepatitis C" seminars are displayed.
Measuring Implementation Strategies to Inform Hepatitis C Quality Improvement: Lessons from the Field
|| Rogal, Shari
Implementation Strategies and the Uptake of Hepatitis C Treatment in VA
|| Rogal, Shari
Focus on Health Equity and Action: Treatment of HCV- ALD Among VHA Vulnerable Populations
|| Julie, Lynch
Focus on Equity and Action—Office of Health Equity Hepatitis C Virus-Advanced Liver Disease Disparities Dashboard
|| Uchendu, Uchenna
Hepatitis C Self-Management Program
|| Weingart, Kimberly
» View more Cyberseminars
There are currently no videos for this topic.
There are currently no podcasts for this topic.